Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluid

Journal of Alzheimer's Disease

Volumn 28, Issue 3, 2012, Pages 625-636

  Vafadar Isfahani, Baharak ^a   Ball, Graham ^a   Coveney, Clare ^a   Lemetre, Christophe ^a   Boocock, David ^a   Minthon, Lennart ^c   Hansson, Oskar ^c   Miles, Amanda Kathleen ^a   Janciauskiene, Sabina M ^e   Warden, Donald ^d   Smith, A David ^d   Wilcock, Gordon ^d   Kalsheker, Noor ^b   Rees, Robert ^a   Matharoo Ball, Balwir ^f   Morgan, Kevin ^b  

^a NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c LUND UNIVERSITY   (Sweden)

^d OPTIMA   (United Kingdom)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Alzheimer's disease; biomarker; MALDI MS; SPARCL1

Indexed keywords

ALBUMIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CYTOKERATIN 1; FIBRINOGEN; OSTEONECTIN; PROTEOME; SPARC LIKE 1 PROTEIN; TETRANECTIN; UNCLASSIFIED DRUG;

ACCURACY; ALBUMIN BLOOD LEVEL; ALZHEIMER DISEASE; ARTICLE; ARTIFICIAL NEURAL NETWORK; BIOINFORMATICS; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MILD COGNITIVE IMPAIRMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 84863229780     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-111505     Document Type: Article

References (49)

1. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schürmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Mühleisen TW, Nöthen MM, Moebus S, Jöckel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41, 1088-1093.
2. Cortes-Canteli M, Strickland S (2009) Fibrinogen, a possible key player in Alzheimer's disease. J Thromb Haemos 7, 146- 150.
3. Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K (2008) Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 4, 38-48.
4. Yin GN, Lee HW, Cho JY, Suk K (2009) Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases. Brain Res 1265, 158-170.
5. Flirski M, Sobow T (2005) Biochemical markers and risk factors of Alzheimer's disease. Curr Alzheimer Res 2, 47-64. (Pubitemid 41389259)
6. Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski JQ (2007) Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov 6, 295-303. (Pubitemid 46505880)
7. Ball G, Mian S, Holding F, Allibone RO, Lowe J, Ali S, Li G, McCardle S, Ellis IO, Creaser C, Rees RC (2002) An integrated approach utilising artificial neural networks and SELDI mass spectrometry for the classification of human tumours and rapid identification of potential biomarkers. Bioinformatics 18, 395-404. (Pubitemid 34284940)
8. Lancashire L, Schmid O, Shah H, Ball G (2005) Classification of bacterial species from proteomic data using combinatorial approaches incorporating artificial neural networks, cluster analysis and principal components analysis. Bioinformatics 21, 2191-2199. (Pubitemid 40731570)
9. Lancashire LJ, Mian S, Ellis IO, Rees RC, Ball GR (2005) Current developments in the analysis of proteomic data: Artificial neural network data mining techniques for the identification of proteomic biomarkers related to breast cancer. Curr Proteomics 2, 15-29. (Pubitemid 40759250)
10. Lancashire LJ, Lemetre C, Ball GR (2009) An introduction to artificial neural networks in bioinformatics-application to complex microarray and mass spectrometry datasets in cancer studies. Briefings Bioinformatics 10, 315-329.
11. Matharoo-Ball B, Ratcliffe L, Lancashire L, Ugurel Selma, Miles AK, Weston DJ, Rees R, Schadendorf D, Ball G, Creaser CS (2007) Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI-TOF mass spectrometry/ bioinformatic approach. Proteomics Clin Appl 1, 605-620.
12. Vafadar-Isfahani B, Laversin SAS, Ahmad M, Ball G, Coveney C, Lemetre C, Miles AK, van Schalkwyk G, Rees R, Matharoo-Ball B (2010) Serum biomarkers which correlate with failure to respond to immunotherapy and tumor progression in a murine colorectal cancer model. Proteomics Clin Appl 4, 682-696.
13. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
14. Mohs RC, Rosen WG, Davis KL (1983) The Alzheimer's disease assessment scale: An instrument for assessing treatment efficacy. Psychopharmacol Bull 19, 448-450. (Pubitemid 13041813)
15. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944. (Pubitemid 14076461)
16. Iversen C, Lancashire L, Waddington M, Forsyth S, Ball G (2006) Identification of Enterobacter sakazakii from closely related species: The use of Artificial Neural Networks in the analysis of biochemical and 16S rDNA data. BMC Microbiol 6, 28.
17. Cortes-Canteli M, Paul J, Norris EH, Bronstein R, Ahn HJ, Zamolodchikov D, Bhuvanendran S, Fenz KM, Strickland S (2010) Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: A possible contributing factor to Alzheimer's disease. Neuron 66, 695-709.
18. Wood H (2010) Alzheimer disease: Fibrinogen links amyloid with vascular dysfunction. Nat Rev Neurol 6, 413.
19. Ahn HJ, Zamolodchikov D, Cortes-Canteli M, Norris EH, Glickman JF, Strickland S (2010) Proc Natl Acad Sci U S A 107, 21812-21817.
20. Clemmensen I, Petersen LC, Kluft C (1986) Purification and characterization of a novel, oligomeric, plasminogen kringle 4 binding protein from human plasma: Tetranectin. Eur J Biochem 156, 327-333.
21. Milojevic J, Melacini G (2011) Stoichiometry and affinity of the human serum albumin-Alzheimer's Aβ peptide interactions. Biophys J 100, 183-192.
22. Laske C (2011) Blood-based biomarkers in Alzheimer disease. Arch Neurol 68, 685-686.
23. Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH (2007) Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann Neurol 61, 120-129. (Pubitemid 46363839)
24. Zellner M, Veitinger M, Umlauf E (2009) The role of proteomics in dementia and Alzheimer's disease. Acta Neuropathol 118, 181-195.
25. Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, Nixon R, Nutt J, Chung K, Zabetian C, Samii A, Lin M, Hattan S, Pan C, Wang Y, Jin J, Zhu D, Li GJ, Liu Y, Waichunas D, Montine TJ, Zhang J (2006) Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 9, 293-348. (Pubitemid 44253348)
26. Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, Perrin RJ, Bales KR, Soares H, Fagan AM, Holtzman DM (2011) Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS One 6, e18850.
27. Johnson G, Brane D, Block W, van Kammen DP, Gurklis J, Peters JL, Wyatt RJ, Kirch DG, Ghanbari HA, Merril CR (1992) Cerebrospinal fluid protein variations in common to Alzheimer's disease and schizophrenia. Appl Theor Electrophor 3, 47-53.
28. Mendis DB, Ivy GO, Brown IR (2000) Induction of SC1 mRNA encoding a brain extracellular matrix glycoprotein related to SPARC following lesioning of the adult rat forebrain. Neurochem Res 25, 1637-1644. (Pubitemid 32052023)
29. Kong W, Mou X, Liu Q, Chen Z, Vanderburg CR, Rogers JT, Huang X (2009) Independent component analysis of Alzheimer's DNA microarray gene expression data. Mol Neurodegener 4, 5.
30. Xu PT, Li YJ, Qin XJ, Scherzer CR, Xu H, Schmechel DE, Hulette CM, Ervin J, Gullans SR, Haines J, Pericak-Vance MA, Gilbert JR (2006) Differences in apolipoprotein E3/3 and E4/4 allele-specific gene expression in hippocampus in Alzheimer disease. Neurobiol Dis 21, 256-275. (Pubitemid 43099851)
31. Haass C (2004) Take five - BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta peptide generation. EMBO J 23, 483-488.
32. Bai Y, Markham K, Chen F, Weerasekera R, Watts J, Horne P, Wakutani Y, Bagshaw R, Mathews PM, Fraser PE, Westaway D, St George-Hyslop P, Schmitt-Ulms G (2008) The in vivo brain interactome of the amyloid precursor protein. Mol Cell Proteomics 7, 15-34.
33. Davidsson P, Sjogren M (2006) Proteome studies of CSF in AD patients. Mech Ageing Dev 127, 133-137. (Pubitemid 43165612)
34. Marchesi VT (2011) Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: Implications for early detection and therapy. FASEB J 25, 5-13.
35. Biere AL, Wood SJ, Wypych J, Steavenson S, Jiang Y, Anafi D, Jacobsen FW, Jarosinski MA, Wu GM, Louis JC, Martin F, Narhi LO, Citron M (2000) Parkinson's disease-associated alpha-synuclein is more fibrillogenic than beta- and gammasynuclein and cannot cross-seed its homologs. J Biol Chem 275, 34574-34579.
36. Pimplikar SW, Nixon RA, Robakis NK, Shen J, Tsai LH (2010) Amyloid-independent mechanisms in Alzheimer's disease pathogenesis. J Neurosci 30, 14946-14954.
37. Obrist P, Spizzo G, Ensinger C, Fong D, Brunhuber T, Schäfer G,Varga M, Margreiter R, Amberger A, Gastl G, Christiansen M (2004) Aberrant tetranectin expression in human breast carcinomas as a predictor of survival. J Clin Pathol 57, 417- 421.
38. Høgdall CK, Høgdall EV, Hørding U, Clemmensen I, Nørgaard-Pedersen B, Toftager-Larsen K (1993) Preoperative plasma tetranectin as a prognostic marker in ovarian cancer patients. Scand J Clin Lab Invest 53, 741-746. (Pubitemid 23350712)
39. Wang ES, Sun Y, Guo JG, Gao X, Hu JW, Zhou L, Hu J, Jiang CC (2010) Tetranectin and apolipoprotein A-I in cerebrospinal fluid as potential biomarkers for Parkinson's disease. Acta Neurol Scand 122, 350-359.
40. Guerreiro N, Gomez-Mancilla B, Williamson B, Minkoff M, Guertin S (2009) Proteomic profiling of cerebrospinal fluid by 8-Plex iTRAQ reveals potential biomarker candidates of Alzheimer's disease. Clin Proteomics 5, 114-124.
41. Merril CR, Harrington MG (1984) "Ultrasensitive" silver stains: Their use exemplified in the study of normal human cerebrospinal fluid proteins separated by two-dimensional electrophoresis. Clin Chem 30, 1938-1942. (Pubitemid 15079381)
42. Davidsson P, Folkesson S, Christiansson M, Lindbjer M, Dellheden B, Blennow K, Westman-Brinkmalm A (2002) Identification of proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing as a prefractionation step followed by two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionisation mass spectrometry. Rapid Commun Mass Spectrom 16, 2083-2088. (Pubitemid 35340074)
43. Maarouf CL, Andacht TM, Kokjohn TA, Castaño EM, Sue LI, Beach TG, Roher AE (2009) Proteomic analysis of Alzheimer's disease cerebrospinal fluid from neuropathologically diagnosed subjects. Curr Alzheimer Res 6, 399-406.
44. Merched A, Serot JM, Visvikis S, Aguillon D, Faure G, Siest G(1998) Apolipoprotein, E, transthyretin and actin in the CSF of Alzheimer's patients: Relation with the senile plaques and cytoskeleton biochemistry. FEBS Lett 425, 225-228. (Pubitemid 28178895)
45. Hammack BN, Fung KY, Hunsucker SW, Duncan MW, Burgoon MP, Owens GP, Gilden DH (2004) Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult Scler 10, 245-260. (Pubitemid 38807450)
46. Hu Y, Hosseini A, Kauwe JSK, Gross J, Cairns NJ, Goate AM (2007) Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease. Proteomics Clin Applicat 1, 1373-1384.
47. Lewczuk P, Esselmann H, Groemer TW, Bibl M, Maler JM, Steinacker P, Otto M, Kornhuber J, Wiltfang J (2004) Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: Evidence of novel biomarkers in Alzheimer's disease. Biol Psychiatry 55, 524-530. (Pubitemid 38338541)
48. Simonsen AH, McGuire J, Podust VN, Davies H, Minthon L, Skoog I, Andreasen N, Wallin A, Waldemar G, Blennow K (2008) Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease. Neurobiol Aging 29, 961- 968.
49. Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, Burkhard P, Hochstrasser DF, Sanchez JC (2003) A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 3, 1486-1494. (Pubitemid 37048074)